Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Total Current Liabilities (2022 - 2025)

Historic Total Current Liabilities for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $37.8 million.

  • BioXcel Therapeutics' Total Current Liabilities rose 4792.03% to $37.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.8 million, marking a year-over-year increase of 4792.03%. This contributed to the annual value of $22.2 million for FY2024, which is 1846.19% down from last year.
  • According to the latest figures from Q3 2025, BioXcel Therapeutics' Total Current Liabilities is $37.8 million, which was up 4792.03% from $33.4 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Total Current Liabilities high stood at $39.4 million for Q3 2023, and its period low was $16.0 million during Q1 2022.
  • Moreover, its 4-year median value for Total Current Liabilities was $27.3 million (2024), whereas its average is $28.4 million.
  • Per our database at Business Quant, BioXcel Therapeutics' Total Current Liabilities skyrocketed by 7977.75% in 2023 and then plummeted by 3514.77% in 2024.
  • Over the past 4 years, BioXcel Therapeutics' Total Current Liabilities (Quarter) stood at $32.9 million in 2022, then dropped by 17.12% to $27.3 million in 2023, then fell by 18.46% to $22.2 million in 2024, then surged by 70.04% to $37.8 million in 2025.
  • Its Total Current Liabilities stands at $37.8 million for Q3 2025, versus $33.4 million for Q2 2025 and $25.5 million for Q1 2025.